Arovella Therapeutics 관리
관리 기준 확인 1/4
Arovella Therapeutics' CEO is Michael Baker, appointed in Jan 2020, has a tenure of 4.83 years. total yearly compensation is A$558.31K, comprised of 60.9% salary and 39.1% bonuses, including company stock and options. directly owns 0.62% of the company’s shares, worth A$1.21M. The average tenure of the management team and the board of directors is 1.5 years and 2.7 years respectively.
주요 정보
Michael Baker
최고 경영자
AU$558.3k
총 보상
| CEO 급여 비율 | 60.9% |
| CEO 임기 | 4.8yrs |
| CEO 소유권 | 0.6% |
| 경영진 평균 재임 기간 | 1.5yrs |
| 이사회 평균 재임 기간 | 2.7yrs |
최근 관리 업데이트
CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2024 | AU$558k | AU$340k | -AU$9m |
| Mar 31 2024 | n/a | n/a | -AU$9m |
| Dec 31 2023 | n/a | n/a | -AU$10m |
| Sep 30 2023 | n/a | n/a | -AU$10m |
| Jun 30 2023 | AU$528k | AU$325k | -AU$10m |
| Mar 31 2023 | n/a | n/a | -AU$9m |
| Dec 31 2022 | n/a | n/a | -AU$9m |
| Sep 30 2022 | n/a | n/a | -AU$9m |
| Jun 30 2022 | AU$604k | AU$303k | -AU$9m |
| Mar 31 2022 | n/a | n/a | -AU$8m |
| Dec 31 2021 | n/a | n/a | -AU$7m |
| Sep 30 2021 | n/a | n/a | -AU$6m |
| Jun 30 2021 | AU$403k | AU$275k | -AU$5m |
| Mar 31 2021 | n/a | n/a | -AU$5m |
| Dec 31 2020 | n/a | n/a | AU$2m |
| Sep 30 2020 | n/a | n/a | -AU$1m |
| Jun 30 2020 | AU$385k | AU$124k | -AU$4m |
보상 대 시장: Michael's total compensation ($USD368.74K) is about average for companies of similar size in the Australian market ($USD299.27K).
보상과 수익: Michael's compensation has increased whilst the company is unprofitable.
CEO
Michael Baker
4.8yrs
테뉴어
AU$558,311
보상
Dr. Michael Baker serves as Chief Executive Officer of Arovella Therapeutics Limited (formerly known as Suda Pharmaceuticals Ltd). since January 2, 2020 and served as its Executive Chairman until July 1, 2...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, MD & Director | 4.8yrs | AU$558.31k | 0.62% A$ 1.2m | |
| Chief Operating Officer | 1.8yrs | AU$423.15k | 0.078% A$ 152.1k | |
| Company Secretary & CFO | less than a year | 데이터 없음 | 데이터 없음 | |
| Administration Manager | 1.3yrs | 데이터 없음 | 데이터 없음 |
1.5yrs
평균 재임 기간
경험이 풍부한 관리: ALA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO, MD & Director | 4.8yrs | AU$558.31k | 0.62% A$ 1.2m | |
| Independent Non-Executive Director | 2.3yrs | AU$84.38k | 0.075% A$ 145.9k | |
| Independent Non-Executive Director | 3yrs | AU$116.13k | 0.072% A$ 141.2k | |
| Non-Executive Chair | 1.7yrs | AU$332.53k | 0.45% A$ 878.3k | |
| Member of Clinical Advisory Board | less than a year | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | less than a year | 데이터 없음 | 데이터 없음 | |
| Member of Clinical Advisory Board & Independent Non-Executive Director | 3.3yrs | AU$115.94k | 0.025% A$ 48.7k | |
| Member of Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.2yrs | 데이터 없음 | 데이터 없음 | |
| Chairman of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Chair of Clinical Advisory Board | less than a year | 데이터 없음 | 데이터 없음 |
2.7yrs
평균 재임 기간
63yo
평균 연령
경험이 풍부한 이사회: ALA's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.